Refractory Follicular Lymphoma Diagnostics Market Trends and Forecasts to 2029 - The Rise of Liquid Biopsy
17 déc. 2024 14h13 HE
|
Research and Markets
Dublin, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The "Refractory Follicular Lymphoma Diagnostics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F" report has been added to...
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
17 déc. 2024 08h00 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
17 déc. 2024 07h00 HE
|
Marker Therapeutics
HOUSTON, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium
10 déc. 2024 08h30 HE
|
Marker Therapeutics
HOUSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
26 nov. 2024 11h00 HE
|
Marker Therapeutics
HOUSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
14 nov. 2024 16h30 HE
|
Marker Therapeutics
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
12 nov. 2024 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and
Provides Business Update
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
14 août 2024 16h30 HE
|
Marker Therapeutics
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of...
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
12 août 2024 07h00 HE
|
Marker Therapeutics
HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
萬聯行在香港獲得Targretin®️（Bexarotene）用於皮膚T細胞淋巴瘤的上市批准
16 juil. 2024 02h54 HE
|
MAIN LIFE CORPORATION LIMITED
香港和澳門的獲批為Targretin®️首次在中國區域內上市Bexarotene為國際臨床慣例用於治療復發性皮膚T細胞淋巴瘤(CTCL)的標準藥物 香港, July 16, 2024 (GLOBE NEWSWIRE) --...